Breast cancer, Bianchini (San Raffaele): “Trastuzumab deruxtecan opens up a new intelligent chemotherapy method”

“Trastuzumab deruxtecan allows us to do chemotherapy in a smarter way than we have always done. This is proof that chemotherapy is not necessarily an antiquated methodology, it can in fact be extremely new if you know how to do it in a more intelligent way.” Thus Giampaolo Bianchini, professor and head of the breast group of the Irccs San Raffaele hospital – Vita-salute San Raffaele university of Milan, on the sidelines of the press conference 'Breast cancer: the new frontiers of treatment', organized in Milan by AstraZeneca and Daiichi Sankyo. At the center of the conference, dedicated to the presentation of new perspectives for the treatment of metastatic breast cancer with low levels of expression of the Her2 receptor, is the monoclonal antibody drug conjugate trastuzumab deruxtecan, whose reimbursement has been approved by Aifa also for this type of patients.